三個皮匠報告
政策庫
new
付費
搜索

表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/-行業數據

表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/
同比增加 14.29%。 公司阿爾茲海默診斷藥物進度靠前，靶向 Aβ蛋白的阿爾茲海默 PET顯像藥物氟[18F]洛貝平已于 2023年 8月遞交 NDA，此外靶向 Tau蛋白的阿爾茲海默 PET顯像藥物 18F-APN-1607也正在 3期臨床當中。18F-LNC1001已進入臨床 3期，前列腺癌診斷核藥市場潛力大。公司也在加快臨床后期產品的引入，2024年 2月從新瑞藥業引入了用于肺癌顯像的氟[18F]阿法肽，從容成醫藥引入了肝功能檢測的
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?32KB 圖片尺寸：2338*914
同報告圖片
 / 77
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第1頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第2頁
fCDnlr7nl4XnsbvlnosgfCDnmb7liIbmr5QgfAp8LS0tLS0tLS0tfC0tLS0tLS0tfAp8IOiCv+eYpOWtpiAgICAgfCA+ODAlICAgfAp8IOelnue7j+eXheWtpiAgIHwgfjklICAgIHwKfCDlv4PohI/nl4XlraYgICB8IH40JSAgICB8Cnwg5YW25LuWICAgICAgIHwgfjclICAgIHwKCui1hOaWmeadpea6kDogTUVEcmF5c2ludGVsbO+8jOWFtOS4muivgeWIuOe7j+a1juS4jumHkeiejeeglOeptumZouaVtOeQhg==
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第3頁
5aW955qE44CCCgrku6XkuIvmmK/lm77niYfkuK3nmoTmlbDmja7vvJoKCnwg5YWo55CD5byA5Y+R5Lit5qC46I2v5oyJ5qC457Sg57G75Z6L5YiS5YiGIHwg55m+5YiG5q+UIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLXwKfCAxOEYsIDY4R2EsIDY0Q3UsIDg5WnIgICAgIHwgPDU1JSAgIHwKfCBPdGhlcnMgICAgICAgICAgICAgICAgICAgIHwgPDI1JSAgIHwKfCA5OW1UYyAgICAgICAgICAgICAgICAgICAgIHwgNyUgICAgIHwKfCAxNzdMdSwgMjI1QWMgICAgICAgICAgICAgIHwgMTUlICAgIHwKCui1hOaWmeadpea6kO+8mk1FRHJheXNpbnRlbGzvvIzlhbTkuJror4HliLjnu4/mtY7kuI7ph5Hono3noJTnqbbpmaLmlbTnkIY=
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第4頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第5頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第6頁
fCDlubTku70gfCDmgLvmoLjoja/msrvnlpfmlbDvvIjkvovmrKHvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18CnwgMjAxNSB8IDYwNTYyNiAgICAgICAgIHwKfCAyMDE3IHwgNjA3MzQ2ICAgICAgICAgfAp8IDIwMTkgfCA1Mjg0ODAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrjgIrlhajlm73moLjljLvlrabmma7mn6XnjrDnirbnroDmiqXjgIvvvIzlhbTkuJror4HliLjnu4/mtY7kuI7ph5Hono3noJTnqbbpmaI=
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第7頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第8頁
5aW955qE44CCCgp8IOS4tOW6iumYtuautSB8IOaVsOmHjyB8IOeZvuWIhuavlCB8CnwgOi0tOiB8IDotLTogfCA6LS06IHwKfCAx5pyf5Li05bqKIHwgMTUzIHwgNzUlIHwKfCAy5pyf5Li05bqKIHwgMTggfCA5JSB8CnwgMS8y5pyf5Li05bqKIHwgMTAgfCA1JSB8CnwgMi8z5pyf5Li05bqKIHwgMyB8IDElIHwKfCAz5pyf5Li05bqKIHwgMjEgfCAxMCUgfAoKPHxvYnNlcnZhdGlvbnw+
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第9頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第10頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第11頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第12頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第13頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第14頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第15頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第16頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第17頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第18頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第19頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第20頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第21頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第22頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第23頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第24頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第25頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第26頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第27頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第28頁
fCDpobnnm64gfCDmlbDmja4gfAp8LS0tLS0tfC0tLS0tLXwKfCDluILlnLrmvZzlipsgfCAkNS0xMEIgfAp8IOaCo+iAhSB8IDIwLTQwSyB8CnwgbUhTUEMgfCB+MTBLIHwKfCBtQ1JQQyAtIDFzdCBMaW5lIHwgfjE1SyB8CnwgbUNSUEMgLSAybmQgTGluZSB8IH41SyB8CnwgbUNSUEMgLSAzcmQgTGluZSB8IDw1SyB8CgrotYTmlpnmnaXmupDvvJpMYW50aGV1c+WFrOWPuOWumOe9ke+8jOWFtOS4muivgeWIuOe7j+a1juS4jumHkeiejeeglOeptumZouaVtOeQhg==
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第29頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第30頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第31頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第32頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第33頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第34頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第35頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第36頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第37頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第38頁
fCDnvo7lm73pnbblkJHogr7nmYzmmL7lg4/liYLluILlnLrnqbrpl7QgfCDmlbDlgLwgIHwKfCAtLS0gfCAtLS0gfAp8IFUuUy4gVEFNIHwgMTcwLDAwMCsgc2NhbnMgIHwKfCAxMTMsMDAwIHwgIHwKfCA1NywwMDAgfCAgfAp8IFUuUy4gdG90YWwgYWRkcmVzc2FibGUgbWFya2V0IChUQU0pIHwgVVNEICQ3NTBNKyB8CgrotYTmlpnmnaXmupDvvJrljLvoja/prZTmlrnvvIzlhbTkuJror4HliLjnu4/mtY7kuI7ph5Hono3noJTnqbbpmaLmlbTnkIY=
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第39頁
fCDpobnnm64gICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5pWw5YC8ICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgVS5TLiBUQU0gICAgICAgICAgICAgICAgICAgICAgICAgfCA5NSwwMDArIHNjYW5zICAgICAgICAgICAgICAgICAgICB8CnwgMjAsMDAxICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMTUsMDAxICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgNjAsMDAwICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgVS5TLiB0b3RhbCBhZGRyZXNzYWJsZSBtYXJrZXQgKFRBTSkgdmFsdWUgfCBVU0QgJDQ3NU0tJDY2NU0gICAgICAgICAgICAgICAgIHwKCgrotYTmlpnmnaXmupDvvJrljLvoja/prZTmlrnvvIzlhbTkuJror4HliLjnu4/mtY7kuI7ph5Hono3noJTnqbbpmaLmlbTnkIY=
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第40頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第41頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第42頁
fCDlubTku70gfCDluILlnLrmvZzlipsgfCDlubTmiavmj4/ph48gfCDliJ3mnJ/nlpHkvLzovaznp7vngbbliIbmnJ8gfCDnlpHkvLzlpI3lj5EgfCBQU01B6Z225ZCR5pS+5bCE5rK755aXIHwKfC0tLS0tLXwtLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDI0IHwgfiQyQiAgICB8IH40NDVLKyAgIHwgfjE0NUsgICAgICAgICAgICAgICB8IH4yNzBLICAgIHwgfjMwSyAgICAgICAgICAgICAgfAp8IDIwMjkgfCAkM0IrICAgIHwgfjcwMEsrICAgfCB+MTc1SyAgICAgICAgICAgICAgIHwgfjMyNUsgICAgfCB+MjIwSyAgICAgICAgICAgICB8
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第43頁
fCDnsbvliKsgICAgICAgfCDmlbDlgLwgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS0tfAp8IFNDUkVFTklORyAgfCB+NzBLICB8CnwgU1RBR0lORyAgICB8IH4yNDBLIHwKfCBNT05JVE9SSU5HIHwgfjIwSyAgfAp8IDIwMjkgICAgICAgfCAgICAgICB8CgrotYTmlpnmnaXmupDvvJpMYW50aGV1c+WFrOWPuOWumOe9ke+8jOWFtOS4muivgeWIuOe7j+a1juS4jumHkeiejeeglOeptumZouaVtOeQhg==
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第44頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第45頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第46頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第47頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第48頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第49頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第50頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第51頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第52頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第53頁
5aW955qE44CCCgp8IOS4tOW6iumYtuautSB8IOaVsOmHjyB8IOeZvuWIhuavlCB8CnwgOi0tOiB8IDotLTogfCA6LS06IHwKfCAx5pyf5Li05bqKIHwgMzk2IHwgNjIlIHwKfCAxLzLmnJ/kuLTluoogfCA3OCB8IDEyJSB8CnwgMuacn+S4tOW6iiB8IDEwMiB8IDE2JSB8CnwgMi8z5pyf5Li05bqKIHwgMTYgfCAzJSB8CnwgM+acn+S4tOW6iiB8IDQ3IHwgNyUgfAoK6LWE5paZ5p2l5rqQ77ya5Yy76I2v6a2U5pa577yM5YW05Lia6K+B5Yi457uP5rWO5LiO6YeR6J6N56CU56m26Zmi5pW055CG
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第54頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第55頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第56頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第57頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第58頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第59頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第60頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第61頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第62頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第63頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第64頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第65頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第66頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第67頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第68頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第69頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第70頁
5aW955qE77yM5Lul5LiL5piv5oKo5Zu+54mH5Lit55qE5pWw5o2u6L2s5o2i5oiQ55qE6KGo5qC877yM5bm25Zyo5LiL5pa55bGV56S65LqG6LWE5paZ5p2l5rqQ77yaCgp8IOiNr+eJqSAgICAgICAgICAgICAgIHwg6Z2254K5ICB8IOmAguW6lOeXhyAgICAgICAgIHwg56CU5Y+R5py65p6EICAgICAgICAgICB8IOS4reWbvemYtuautSB8IOmmluasoeWFrOekuuaXpeacnyB8IOmihOiuoeWujOaIkOaXpeacnyB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwKfCDmsJ9bMThGXeWMlumSoO+8iDPnsbvvvIkgIHwgLyAgICAgfCDpqqhQRVTmmL7lg48gICAgICB8IOWOn+WtkOmrmOenkSAgICAgICAgICAgIHwgM+acn+WujOaIkCAgfCAyMDIxLTIgICAgICAgfCAyMDIyLTkgICAgICAgfAp8IOawn1sxOEZd5Y+45LuW5piOICAgICAgIHwgUFNNQSAgfCDliY3liJfohbrnmYxQRVTmmL7lg498IOWOn+WtkOmrmOenkS9GdXR1cmVDaGVtIHwgM+acnyAgICAgIHwgMjAyMy0xMSAgICAgIHwgLyAgICAgICAgICAgIHwKfCDplLZbOTltVGNd56Gr6IO25L2T77yIM+exu++8iXwgLyAgICAgfCDkubPohbrnmYxTUEVDVOaYvuWDj3wg5Y6f5a2Q6auY56eRICAgICAgICAgICAgfCAz5pyfICAgICAgfCAyMDIzLTEyICAgICAgfCAvICAgICAgICAgICAgfAp8IOmVpVsxNzdMdV3msKflpaXmm7Logr3vvIgz57G777yJfFNTVFIgIHwg56We57uP5YaF5YiG5rOM55ik5rK755aXIHwg5Y6f5a2Q6auY56eRICAgICAgICAgICAgfCAz5pyfICAgICAgfCAyMDIzLTEyICAgICAgfCAvICAgICAgICAgICAgfAp8IOmVpVs2OEdhXeWkmueJueWuieiCve+8iDPnsbvvvIl8U1NUUiAgfCDnpZ7nu4/lhoXliIbms4znmKRQRVTmmL7lg48gfCDljp/lrZDpq5jnp5EgICAgICAgICAgICB8IDPmnJ8gICAgICB8IDIwMjQtMSAgICAgICB8IC8gICAgICAgICAgICB8Cnwg56KYWzEzMUld6IuE6ION77yIM+exu++8iSAgfCAvICAgICB8IFBQR0wgU1BFQ1TmmL7lg48gfCDljp/lrZDpq5jnp5EgICAgICAgICAgICB8IDPmnJ8gICAgICB8IDIwMTgtNiAgICAgICB8IC8gICAgICAgICAgICB8Cnwg5rCfWzE4Rl3otJ3ku5bll6ogICAgICAgfCBBQiAgICB8IOmYv+WwlOWFuea1t+m7mFBFVOaYvuWDjyB8IOWOn+WtkOmrmOenkSAgICAgICAgICAgIHwgMuacnyAgICAgIHwgMjAyMS02ICAgICAgIHwgMjAyNC03ICAgICAgIHwKfCDmsJ9bMThGXeWkmuW3tO+8iDPnsbvvvIkgIHwgUFNNQSAgfCDluJXph5Hmo67nl4VQRVTmmL7lg48gfCDljp/lrZDpq5jnp5EgICAgICAgICAgICB8IOiOt+aJueS4tOW6iiB8IDIwMjMtNCAgICAgICB8IC8gICAgICAgICAgICB8Cnwg6ZOKWzEwM1BiXeWvhuWwgeexvea6kCAgIHwgLyAgICAgfCDliY3liJfohbrnmYzmsrvnlpcgICB8IOWOn+WtkOmrmOenkSAgICAgICAgICAgIHwg5Li05bqK5YmN5a6M5oiQIHwgLyAgICAgICAgICAgIHwgLyAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWMu+iNr+mtlOaWue+8jOWFtOS4muivgeWIuOe7j+a1juS4jumHkeiejeeglOeptumZouaVtOeQhg==
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第71頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第72頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第73頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第74頁
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第75頁
fCDoja/niakgICAgICAgICB8IOmdtueCuSB8IOeUqOmAlCB8IOmAguW6lOeXhyAgIHwg5qC457SgICB8IOWFrOWPuCAgICAgICAgICAgICAgICAgICAgICAgICB8IOS4reWbveiOt+aJueaXtumXtCB8IOexu+WeiyB8IOWbveWutuWMu+S/nSB8CnwtLS0tLS0tLS0tLS0tLXwtLS0tLS18LS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tfC0tLS0tLS0tLS18Cnwg5rCfWzE4Rl3otJ3ku5bntKIgICB8IEHOsiAgIHwg6K+K5patIHwg6Zi/5bCU5YW55rW36buYUEVU5pi+5YOPIHwgMThGICAgfCBMaWZlIE1vbGVjdWxhciBJbWFnaW5nL+WFiOmAmuWMu+iNryB8IDIwMjMtOSAgICAgICB8IOWIm+aWsOiNryB8IOWQpiAgICAgICB8Cnwg5rCv5YyW6ZS2Wzg5U3JdICAgfCAvICAgIHwg5rK755aXIHwg55mM55eH6aqo6L2s56e777yb55a855ebIHwgODlTciAgfCBHRS/ljp/lrZDnp5HlhbQgICAgICAgICAgICAgICAgICAgfCAyMDA0LTggICAgICAgfCDljp/noJToja8gfCDlkKYgICAgICAgfAp8IOmTils5OW1UY13mm7/mm7LohqYgfCAvICAgIHwg6K+K5patIHwg5b+D6IKM54GM5rOoU1BFQ1TmmL7lg48gfCA5OW1UYyB8IEdFL+i/quenkSAgICAgICAgICAgICAgICAgICAgICAgfCAyMDAzLTMgICAgICAgfCDljp/noJToja8gfCDlkKYgICAgICAgfAp8IOawn1sxOEZd6ISx5rCn6JGh57OWIHwgLyAgICB8IOiviuaWrSB8IOivhOS8sOiCv+eYpOOAgeWGoOW/g+eXheOAgeeZq+eXq+aCo+iAheeahOW8guW4uOezluS7o+iwouaDheWGtSB8IDE4RiAgIHwg5Y6f5a2Q6auY56eRICAgICAgICAgICAgICAgICAgICAgICB8IDIwMDUtMiAgICAgICB8IOWIm+aWsOiNryB8IOWQpiAgICAgICB8Cnwg6ZKHWzkwWV3moJHohILlvq7nkIMgfCAvICAgIHwg5rK755aXIHwg57uT55u06IKg55mM6IKd6L2s56e75oKj6ICFIHwgOTBZICAgfCBTaXJ0ZXgv6L+c5aSn5Yy76I2vICAgICAgICAgICAgICAgfCAyMDIyLTEgICAgICAgfCDliJvmlrDoja8gfCDlkKYgICAgICAgfAp8IOawr+WMlumVrVsyMjNSYV0gICB8IC8gICAgfCDmsrvnlpcgfCDliY3liJfohbrnmYwgfCAyMjNSYSB8IOaLnOiAsyAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyMDIwLTggICAgICAgfCDliJvmlrDoja8gfCDlkKYgICAgICAgfAp8IOeimFsxMzFJXeWvhuWwgeexvea6kCB8IC8gICAgfCDmsrvnlpcgfCDkuI3lj6/liIfpmaTjgIHmnKrmtbjmtqbjgIHnlJ/plb/pgJ/njofmhaLogIzlr7nkvY7jgIHkuK3luqbmlL7lsITnur/mlY/mhJ/nmoTogr/nmKQgfCAxMzFJICB8IOaZuuWNmumrmOenkSAgICAgICAgICAgICAgICAgICAgICAgfCAyMDA4LTEgICAgICAgfCDliJvmlrDoja8gfCDlkKYgICAgICAgfAp8IOeimFsxMzFJXeWMlumSoCAgICB8IC8gICAgfCDmsrvnlpcv6K+K5patIHwg55Sy54q26IW655mM5Y+K55Sy5LqiIHwgMTMxSSAgfCDmoLjniannkIbkuI7ljJblrabnoJTnqbbmiYAgICAgICAgICAgICAgfCAyMDA0LTEyICAgICAgfCDliJvmlrDoja8gfCDmmK8gICAgICAgfAp8IOeimFsxMzFJXee+juWmpeaYlOWNleaKlyB8IEJTRyAgfCDmsrvnlpcgfCDogp3nmYwgfCAxMzFJICB8IOWNjuelnueUn+eJqSAgICAgICAgICAgICAgICAgICAgICAgfCAyMDA1LTQgICAgICAgfCDliJvmlrDoja8gfCDlkKYgICAgICAgfAp8IOmUtls5OW1UY13kuprnlLLln7rkuozohqbphbjnm5AgfCAvICAgIHwg5rK755aXIHwg57G76aOO5rm/5oCn5YWz6IqC54KOIHwgOTltVGMgfCDkupHlhYvoja/kuJogICAgICAgICAgICAgICAgICAgICAgIHwgMjAwMCAgICAgICAgIHwg5Yib5paw6I2vIHwg5ZCmICAgICAgIHwKfCDmsK/ljJbkuprpk4pbMjAxVGxdIHwgLyAgICB8IOiviuaWrSB8IOW/g+iCjOeBjOazqOaYvuWDjyB8IDIwMVRsIHwg5Y6f5a2Q6auY56eRICAgICAgICAgICAgICAgICAgICAgICB8IDE5OTYgICAgICAgICB8IOWIm+aWsOiNryB8IOWQpiAgICAgICB8Cnwg6ZSdWzk5bVRjXeeUsuawp+W8guiFiCB8IC8gICAgfCDor4rmlq0gfCDlv4PogoznvLrooYDjgIHlv4PogozmopfloZ7jgIHnlLLnirbohbrnlr7nl4Xor4rmlq0gfCA5OW1UYyB8IOWOn+WtkOenkeWFtOOAgeaso+enkeWMu+iNr+OAgeWOn+WtkOmrmOenkeOAgeW4jOWfg+WMu+iNr+OAgeWOn+WtkOmrmOenkeWQjOS9jee0oCB8IDE5OTcgICAgICAgICB8IOWIm+aWsOiNryB8IOWQpiAgICAgICB8Cnwg6ZSdWzk5bVRjXeWWt+abv+mFuOebkCB8IC8gICAgfCDor4rmlq0gfCDogr7liqjmgIHmmL7lg4/jgIHogr7lip/og73mtYvlrprjgIHogr7lsI/nkIPmu6Tov4fnjofmtYvph4/lkoznm5HmtYvnp7vmpI3ogr7nrYkgfCA5OW1UYyB8IOWOn+WtkOenkeWFtOOAgeaso+enkeWMu+iNr+OAgeWOn+WtkOmrmOenkeOAgeW4jOWfg+WMu+iNr+OAgeWOn+WtkOmrmOenkeWQjOS9jee0oCB8IDE5OTcgICAgICAgICB8IOWIm+aWsOiNryB8IOWQpiAgICAgICB8Cnwg6ZSdWzk5bVRjXeWPjOWNiuiDseS5memFryB8IC8gICAgfCDor4rmlq0gfCDnmavnl6vlkozohJHljZLkuK3jgIHohJHnmKTnrYnnlr7nl4XnmoTohJHooYDmtYHngYzms6jmmL7lg48gfCA5OW1UYyB8IOWOn+WtkOenkeWFtOOAgeaso+enkeWMu+iNr+OAgeWOn+WtkOmrmOenkeOAgeW4jOWfg+WMu+iNr+OAgeWOn+WtkOmrmOenkeWQjOS9jee0oCB8IDE5OTcgICAgICAgICB8IOWIm+aWsOiNryB8IOWQpiAgICAgICB8Cnwg6ZSdWzk5bVRjXeS6mueUsuWfuuS6jOiGpumFuOebkCB8IC8gICAgfCDor4rmlq0gfCDpqqjmmL7lg48gfCA5OW1UYyB8IOWOn+WtkOenkeWFtOOAgeaso+enkeWMu+iNr+OAgeWOn+WtkOmrmOenkeOAgeW4jOWfg+WMu+iNr+OAgeWOn+WtkOmrmOenkeWQjOS9jee0oCB8IDE5OTcgICAgICAgICB8IOWIm+aWsOiNryB8IOWQpiAgICAgICB8Cnwg6auY6ZSdWzk5bVRjXemFuOmSoCB8IC8gICAgfCDor4rmlq0gfCDnlLLnirbohbrmmL7lg4/jgIHohJHmmL7lg4/jgIHllL7mtrLohbrmmL7lg4/jgIHlvILkvY3og4PnspjohpzmmL7lg48gfCA5OW0=
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第76頁
5aW955qE77yM5Lul5LiL5piv6KGo5qC85pWw5o2u77yaCgp8IOiNr+eJqSAgICAgICAgIHwg5YWs5Y+4L+acuuaehCAgICAgICAgIHwg6Z2254K5IHwg55So6YCUIHwg6YCC5bqU55eHICAgICAgIHwg5qC457SgIHwg5Lit5Zu95pyA6auY6Zi25q61IHwg6aaW5qyh5YWs56S65pel5pyfIHwg6aKE6K6h5a6M5oiQ5pel5pyfIHwKfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tfC0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18Cnwg5rCfWzE4Rl3mtJvotJ3lubMqIHwg5qyj5qGQ5Yy76I2vL+Wuiei/quenke+8iOS4nOivmuiNr+S4mu+8iSB8IEHOsiAgIHwg6K+K5patIHwg6Zi/5bCU5YW55rW36buYUEVU5pi+5YOPIHwgMThGICB8IOS4iuW4gueUs+ivtyAgICAgIHwgMjAyMy04ICAgICAgIHwgLyAgICAgICAgICAgIHwKfCDmsJ9bMThGXeWMlumSoCogICB8IOWOn+WtkOmrmOenke+8iOS4reWbveWQjOi+kO+8iSAgICAgICB8IC8gICAgfCDor4rmlq0gfCDpqqhQRVTmmL7lg48gICAgfCAxOEYgIHwg5LiK5biC55Sz6K+3ICAgICAgfCAyMDIyLTEyICAgICAgfCAvICAgICAgICAgICAgfAp8IOmVk1s2OEdhXeWkmueJueWuieiCvSogfCDljp/lrZDpq5jnp5HvvIjkuK3lm73lkIzovpDvvIkgICAgICAgfCBTU1RSIHwg6K+K5patIHwg56We57uP5YaF5YiG5rOM55ikUEVU5pi+5YOPIHwgNjhHYSB8IDPmnJ8gICAgICAgICAgIHwgMjAyNC0xICAgICAgIHwgLyAgICAgICAgICAgIHwKfCDnophbMTIzSV3msJ/mvZggICB8IEdFICAgICAgICAgICAgICAgIHwgREFUICB8IOiviuaWrSB8IOW4lemHkeajrlNQRUNU5pi+5YOPIHwgMTIzSSB8IDPmnJ/lrozmiJAgICAgICAgfCAyMDE5LTEyICAgICAgfCAyMDIyLTEyICAgICAgfAp8IOawn1sxOEZd5Y+45LuW5piOICAgfCBGdXR1cmVDaGVtL+WOn+WtkOmrmOenke+8iOS4reWbveWQjOi+kO+8iSB8IFBTTUEgfCDor4rmlq0gfCDliY3liJfohbrnmYxQRVTmmL7lg48gfCAxOEYgIHwgM+acnyAgICAgICAgICAgfCAyMDIzLTUgICAgICAgfCAyMDI1LTEgICAgICAgfAp8IDE3N0x1LVBTTUEtNjE3IHwg6K+65Y2OICAgICAgICAgICAgICB8IFBTTUEgfCDmsrvnlpcgfCDmv4DntKDmlY/mhJ/mgKfliY3liJfohbrnmYwgfCAxNzdMdSB8IDPmnJ8gICAgICAgICAgIHwgMjAyMS0xICAgICAgIHwgMjAyNi0yICAgICAgIHwKfCDnophbMTMxSV3oi4Tog40qICAgfCDljp/lrZDpq5jnp5HvvIjkuK3lm73lkIzovpDvvIkgICAgICAgfCBORVQgIHwg6K+K5patL+ayu+eWlyB8IOWXnOmTrOe7huiDnueYpOaIluWJr+elnue7j+iKgueYpFNQRUNU5pi+5YOPIHwgMTMxSSB8IDPmnJ8gICAgICAgICAgIHwgMjAxOC0xMCAgICAgIHwgLyAgICAgICAgICAgIHwKfCBUTFg1OTEtQ0R4ICAgIHwgVGVsaXjljLvoja8gICAgICAgICB8IFBTTUEgfCDor4rmlq0gfCDliY3liJfohbrnmYxQRVTmmL7lg48gfCA2OEdhIHwgM+acnyAgICAgICAgICAgfCAyMDIzLTUgICAgICAgfCAyMDI2LTcgICAgICAgfAp8IOawn1sxOEZd5oCd552/6IK9ICAgfCDok53nurPmiJDvvIjkuJzor5roja/kuJrvvIkgICAgICAgICB8IFBTTUEgfCDor4rmlq0gfCDliY3liJfohbrnmYxQRVTmmL7lg48gfCAxOEYgIHwgM+acnyAgICAgICAgICAgfCAyMDIzLTEyICAgICAgfCAvICAgICAgICAgICAgfAp8IGZsb3Jvem9sb3RhdSAoMThGKSB8IOaWsOaXreeUn+aKgC/kuJzor5roja/kuJogICAgICAgfCBUYXUgIHwg6K+K5patIHwg6Zi/5bCU5YW55rW36buYUEVU5pi+5YOPIHwgMThGICB8IDPmnJ8gICAgICAgICAgIHwgMjAyMS05ICAgICAgIHwgLyAgICAgICAgICAgIHwKfCA2OEdhLVBTTUEtNjE3IHwg6K+65Y2OICAgICAgICAgICAgICB8IFBTTUEgfCDor4rmlq0gfCDmv4DntKDmlY/mhJ/mgKfliY3liJfohbrnmYxQRVTmmL7lg48gfCA2OEdhIHwgM+acnyAgICAgICAgICAgfCAyMDIyLTYgICAgICAgfCAvICAgICAgICAgICAgfAp8IOmVpVsxNzdMdV3msKflpaXmm7Logr0qIHwg5YWI6YCa5Yy76I2vICAgICAgICAgIHwgU1NUUiB8IOayu+eWlyB8IOiDg+iCoOiDsOelnue7j+WGheWIhuazjOiCv+eYpCB8IDE3N0x1IHwgM+acnyAgICAgICAgICAgfCAyMDIzLTYgICAgICAgfCAyMDMwLTEwICAgICAgfAp8IOmVpVsxNzdMdV3msKflpaXmm7Logr0qIHwg5oGS55Ge5Yy76I2vICAgICAgICAgIHwgU1NUUiB8IOayu+eWlyB8IOiDg+iCoOiDsOelnue7j+WGheWIhuazjOiCv+eYpCB8IDE3N0x1IHwgM+acnyAgICAgICAgICAgfCAyMDIzLTYgICAgICAgfCAyMDMwLTEwICAgICAgfAp8IOmVpVsxNzdMdV3msKflpaXmm7Logr0qIHwg5Y6f5a2Q6auY56eR77yI5Lit5Zu95ZCM6L6Q77yJICAgICAgIHwgU1NUUiB8IOayu+eWlyB8IOiDg+iCoOiDsOelnue7j+WGheWIhuazjOiCv+eYpCB8IDE3N0x1IHwgM+acnyAgICAgICAgICAgfCAyMDI0LTEgICAgICAgfCAvICAgICAgICAgICAgfAp8IOmUnVs5OW1UY13noavog7bkvZMgfCDljp/lrZDpq5jnp5HvvIjkuK3lm73lkIzovpDvvIkgICAgICAgfCAvICAgIHwg6K+K5patIHwg5Lmz6IW655mM5oKj6ICF5YmN5ZOo5reL5be057uT56S66LiqIHwgOTltVGMgfCAz5pyfICAgICAgICAgICB8IDIwMjMtMTIgICAgICB8IC8gICAgICAgICAgICB8Cnwg6ZKHOTDnjrvnkoPlvq7nkIMgICB8IOazouWjq+mhv+enkeWtpiAgICAgICAgfCAvICAgIHwg5rK755aXIHwg6IKd55mMICAgICAgICAgfCA5MFkgIHwgM+acnyAgICAgICAgICAgfCAyMDIxLTggICAgICAgfCAyMDI2LTEwICAgICAgfAp8IOawn1sxOEZd6Zi/
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第77頁
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
表22、東誠藥業主要在研核藥管線首次公預計完藥物靶點適應癥研發機構中國階段示日期成日期氟[18F]洛貝平（3類）Aβ阿爾茲海默PET顯像安迪科/欣翮醫藥NDA2023-8/18F-LNC1001PSMA前列腺癌PET顯像藍納成3期2023-12/_第78頁
所屬報告： 醫藥行業核藥深度報告：診療一體化優勢顯著海內外加快產業布局-240412（50頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站